Nanotechnology in Uveal Melanoma: Cutting-Edge Advances to Halt Progression and Metastasis

Uveal melanoma (UM) represents the most prevalent primary intraocular malignancy in adults, distinguished by its aggressive progression and significant propensity for metastasis, predominantly to the liver and lungs. Despite advances in diagnostic tools and therapeutic approaches, the prognosis for metastatic UM remains dismal, underlining the critical need for novel treatment regimens. Nanotechnology is an exciting new area in the treatment of UM that offers creative ways to get around the problems with current medicines. Nanocarrier systems, including albumin-based nanoparticles, PEGylated nanostructured lipid carriers, nanostructured lipid carriers, and gold nanoparticles, facilitate targeted drug delivery, enhance bioavailability, and allow for controlled release. These advancements contribute to improved therapeutic outcomes while simultaneously reducing off-target effects. Recent advancements in nanotechnology have demonstrated considerable promise in the prevention of metastasis by facilitating early intervention and enabling the targeted delivery of chemotherapeutic agents or immune modulators directly to the tumor microenvironment. Furthermore, nanotechnology-based systems are being investigated for the delivery of RNA therapies and gene-editing tools, offering a fresh approach to tackling the genetic foundations of UM. Preclinical and clinical investigations have shown encouraging results, with nanotechnology-enhanced medicines demonstrating higher effectiveness, lower toxicity, and increased patient compliance. Recently, new ideas have been talked about in this study, like theranostic systems and stimuli-responsive nanocarriers, which can do both diagnostic and medicinal work. This makes personalized medicine possible in UM treatment. To summarize, nanotechnology has enormous potential for revolutionizing the therapeutic landscape for UM, especially in terms of medication delivery and metastasis prevention. Further research and practical translation of these technologies are required to enhance UM patients' survival rates and quality of life.